Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion - Episode 11
How BTK Inhibitors Might Address Unmet Treatment Needs in CSU
Published on:
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors appear to offer faster symptom relief and higher complete response rates compared with current chronic spontaneous urticaria (CSU) treatments like antihistamines and omalizumab while potentially requiring less frequent dosing and showing favorable safety profiles.
Video content above is prompted by the following:
- How do data from these trials compare to results you see in practice with other, non-BTK options for CSU management?
